The application for the renewal of the approval of the active substance daminozide was submitted on 27 February 2013 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 15 April 2013 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 31 October 2018, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 14 June and 14 August 2023. On 3 January 2020, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 3 February 2020 within the deadline given. On 18 August 2020, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 15 February 2023 within the deadline given. On 18 December 2024, the Authority adopted its conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance daminozide in the Standing Committee on Plants, Animals, Food and Feed on 11 March 2025, during which uncertainties concerning non-dietary exposure, the reliability of key toxicological studies and risk assessment for operators, workers, residents and bystanders were identified. Therefore, on 18 November 2025, the Commission submitted a mandate to the Authority to reevaluate together with the rapporteur Member State some of the information available in the application and to update its conclusion. The rapporteur Member State submitted the updated renewal assessment report in February 2026 to the Authority, which is expected to update its conclusion on daminozide by the end of November 2026. As additional time will be necessary for the delivery of the opinion of the Standing Committee and for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 15 months, until 15 December 2027.
Recital 27, Regulation (EU) 2026/1826
In forcesince 28 Jul 2026